Thus, it is important to dissect the characteristic stromal–epithelial CAV1 alterations within PCa, as a ‘simple’ CAV1-targeting would only achieve radiosensitization at the levels of tumor cells while a stromal CAV1 loss would counteract a desired therapeutic benefit. The gene discussed is CAV1; the disease is posterior cortical atrophy.